Raymond James analyst Steven Seedhouse lowered the firm’s price target on Mirum Pharmaceuticals to $81 from $83 and keeps a Strong Buy rating on the shares. Mirum’s preliminary worldwide net sales figure for Livmarli of roughly $29M is above both consensus and the firm’s estimate of $24.9M, the analyst tells investors in a research note.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on MIRM:
- Mirum Pharmaceuticals prices upsize $275M convertible senior note offering
- Mirum Pharmaceuticals offers to sell $200M in convertible senior notes
- 3 Stocks to Buy Today, 3/15/2023, According to Top Analysts
- Mirum Pharmaceuticals reports Q4 revenue $27.91M, consensus $24.57M
- Mirum Pharmaceuticals price target lowered to $61 from $69 at H.C. Wainwright
